API &
Intermediates

Welcome to Aurore Life Sciences, a specialized pure-play API manufacturer. As a vital link in pharmaceutical drug manufacturing, we are your trusted partner for all your API & Intermediates requirements. Our unwavering commitment to excellence, innovation, and uncompromising quality sets us apart as leaders in Active Pharmaceutical Ingredient (API) production. With a growing legacy, we are dedicated to advancing healthcare through cutting-edge API manufacturing, empowering formulation manufacturers for a future of continued progress and positive impact.

Our

Approach

Aurore’s Key strength is fuelled by early identification, building robust API processes, and targeting early launch opportunities in key markets through complete backward integration. Our capabilities and capacities cater to diverse product markets globally, making us the ideal global partners.

Product

List

Acyclovir

Antiviral

  • Filing status

    CEP/EDMF, TDMF, USDMF

  • Capacity

    30,240 MT Annually

plus-icon
Amlodipine Besilate

Anti-Hypertensive

  • Filing status

    Brazil DMF, CEP/EDMF, MFDS, NMPA, Russia DMF, USDMF

  • Capacity

    180 MT Annually

plus-icon
Bemotrizinol

Antivertigo Preparations

  • Capacity

    8,100 MT Annually

plus-icon
Bilastine

Anti Histamine

  • Filing status

    ASMF, USDMF

  • Capacity

    28,800 MT Annually

plus-icon
Bisoprolol Fumarate

Antihypertensive

  • Capacity

    15,840 MT Annually

plus-icon
Camostat

Anti-inflammatory

  • Filing status

    MFDS

  • Capacity

    50,400 MT Annually

plus-icon
Celecoxib

Anti-inflammatory

  • Filing status

    Brazil DMF, CEP/EDMF, Japan DMF, MFDS, USDMF

  • Capacity

    1,62,000 MT Annually

plus-icon
Citicoline Sodium

Psychostimulants

  • Capacity

    13,200 MT Annually

plus-icon
Clopidogrel Bisulphate

Antiplatelet Agents

  • Capacity

    93,600 MT Annually

plus-icon
Clozapine

Anti-inflammatory

  • Filing status

    Canada DMF, CEP/EDMF, Russia DMF, USDMF

  • Capacity

    52,800 MT Annually

plus-icon
Dabigatran Etexilate Mesilate

Anti-Coagulant

  • Filing status

    CEP/EDMF, USDMF

  • Capacity

    8,100 MT Annually

plus-icon
Dapagliflozin

Anti-Diabetic

  • Filing status

    CEP/EDMF

  • Capacity

    - MT Annually

plus-icon
Darunavir

Protease Inhibitors

  • Capacity

    6,000 MT Annually

plus-icon
Des Venlafaxine Oxalate

Antihypertensive

  • Capacity

    9,600 MT Annually

plus-icon
Desvenlafaxine Succinate

Anti-Depressant

  • Filing status

    Brazil DMF, USDMF

  • Capacity

    34,800 MT Annually

plus-icon
Dolutegravir

Antihypertensive

  • Filing status

    WHO DMF

  • Capacity

    15,480 MT Annually

plus-icon
Dolutegravir sodium

Anti-Retroviral

  • Filing status

    WHO

  • Capacity

    50 MT Annually

plus-icon
Dronaderone

Anti-Arrhythmic

  • Filing status

    ASMF, CEP/EDMF, Israil, MFDS, NMPA, USDMF

  • Capacity

    85,860 MT Annually

plus-icon
Edoxaban Tosylate

Anti-Coagulant

  • Capacity

    5 - 6 MT Annually

plus-icon
Eltrombopog Olamine

Immuno-Suppressant

  • Filing status

    CEP/EDMF

  • Capacity

    2 MT per month

plus-icon
Empagliflozin

Anti-Diabetic

  • Filing status

    Commercial

  • Capacity

    - MT Annually

plus-icon
Erdosteine

Mucolytic

  • Filing status

    ASMF, MFDS

  • Capacity

    69,300 MT Annually

plus-icon
Etoricoxib

Anti-inflammatory

  • Filing status

    ASMF, Brazil DMF, Egypt DMF, Malaysia DMF, NMPA, PPB-MOH-KENYA, SAHPRA MOH, Singapore DMF

  • Capacity

    30,240 MT Annually

plus-icon
Favipiravir

Antiviral

  • Filing status

    Indonesia MOH, Malaysia DMF, USDMF, Vietnam

  • Capacity

    51,600 MT Annually

plus-icon
Fesoterodine

Antimuscarinics

  • Filing status

    USDMF

  • Capacity

    1,680 MT Annually

plus-icon
Fimasartan
  • Filing status

    MFDS

  • Capacity

    15,840 MT Annually

plus-icon
Flecainide Acetate

Anti-Arrhythmic

  • Filing status

    CEP/EDMF

  • Capacity

    28,800 MT Annually

plus-icon
fluphenazine hydrochloride

Antihypertensive

  • Filing status

    USDMF

  • Capacity

    1,920 MT Annually

plus-icon
Indomethacin

Anti-Inflammatory

  • Filing status

    USDMF

  • Capacity

    1,440 MT Annually

plus-icon
Lamivudine

Antiviral

  • Capacity

    4,080 MT Annually

plus-icon
Levetiracetam

Anti-Epileptic

  • Filing status

    CEP/EDMF, USDMF

  • Capacity

    48,000 MT Annually

plus-icon
Levothyroxine

Hypothyroidism

  • Filing status

    CEP/EDMF, NMPA, USDMF

  • Capacity

    1 MT Annually

plus-icon
Levothyroxine Sodium

Harmones

  • Filing status

    CEP/EDMF, Iran DMF, NMPA, USDMF

  • Capacity

    540 MT Annually

plus-icon
Linagliptin

Anti-Diabetic

  • Capacity

    28,800 MT Annually

plus-icon
Losartan Potassium

Angiotensin Receptor Blockers (ARBs)

  • Filing status

    CEP/EDMF

  • Capacity

    10,800 MT Annually

plus-icon
Marbofloxacin

Veterinary medicine

  • Filing status

    CEP/EDMF, USDMF

  • Capacity

    27,600 MT Annually

plus-icon
Memantine

Alzheimer disease

  • Capacity

    2 MT Annually

plus-icon
Mesalamine

Anti-Inflammatory

  • Capacity

    23,400 MT Annually

plus-icon
Molnupiravir

Antiviral

  • Filing status

    GHANA FDA, Indonesia MOH, Malaysia DMF, Mozambique MOH, RWANDA FDA, SAHPRA MOH, Tanzania MOH, Uganda FDA, Vietnam, WHO DMF

  • Capacity

    3,600 MT Annually

plus-icon
Nafamostat

broad-spectrum, synthetic serine protease inhibitor

  • Filing status

    MFDS, NMPA, USDMF

  • Capacity

    2,400 MT Annually

plus-icon
Nirmatrelvir

oral protease inhibitor

  • Filing status

    WHO DMF

  • Capacity

    4,800MT Annually

plus-icon
Olanzapine

Anti-Psychotic

  • Capacity

    20,400 MT Annually

plus-icon
Olopatadiane

Anti-Allergic

  • Capacity

    34,800 MT Annually

plus-icon
Oxcarbazepine

Anticonvulsants

  • Filing status

    CEP/EDMF, USDMF

  • Capacity

    40,800 MT Annually

plus-icon
Pinaverium Bromide

IBS

  • Filing status

    NMPA

  • Capacity

    5,100 MT Annually

plus-icon
Prazosin HCl

Anti-Hypertensive

  • Filing status

    USDMF

  • Capacity

    2,400 MT Annually

plus-icon
Raloxifene

selective estrogen receptor modulators (SERMs)

  • Filing status

    CEP/EDMF, MFDS, USDMF

  • Capacity

    3,600 MT Annually

plus-icon
Ramelteon

Sedative

  • Filing status

    Iran DMF

  • Capacity

    5,280 Annually

plus-icon
Rebamipide

Category C

  • Filing status

    MFDS

  • Capacity

    38,700 MT Annually

plus-icon
Remdesivir

Antiviral

  • Capacity

    720 MT Annually

plus-icon
Risperidone

Antiviral

  • Capacity

    39,600 MT Annually

plus-icon
Sacubitril

Angiotensin Receptor Neprilysin Inhibitor (ARNI)

  • Capacity

    45,000 MT Annually

plus-icon
Salsalate

Anti-Inflammatory

  • Filing status

    USDMF

  • Capacity

    81,000 MT Annually

plus-icon
Sodium Cromoglycate

Anti-Allergic/ Anti-Asthma

  • Capacity

    18,000 MT Annually

plus-icon
Sulindac

Anti-inflammatory

  • Filing status

    USDMF

  • Capacity

    32,400 MT Annually

plus-icon
Tafamidis

Transthyretin Stabilizer

  • Filing status

    USDMF

  • Capacity

    1,800 MT Annually

plus-icon
Tenofover

Anti-Retroviral

  • Capacity

    17,100 MT Annually

plus-icon
Tofacitinib

Immunosuppressant

  • Filing status

    NMPA, USDMF

  • Capacity

    10,080 MT Annually

plus-icon
Tolvaptan

Diuretic

  • Filing status

    ASMF, NMPA, USDMF

  • Capacity

    1,800 MT Annually

plus-icon
Valacyclovir

Antiviral

  • Filing status

    Brazil DMF, CEP/EDMF, Iran DMF, PPB-MOH-KENYA, Singapore DMF, TGA DMF, USDMF

  • Capacity

    59,136 MT Annually

plus-icon
Valganciclovir

Antiviral

  • Filing status

    Malaysia DMF, NMPA, USDMF

  • Capacity

    12,600 MT Annually

plus-icon
Verapamil

Anti-Arrhythmic

  • Filing status

    CEP/EDMF, NMPA, USDMF

  • Capacity

    43,200 MT Annually

plus-icon

Disclaimer: No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.

Why Choose

Aurore Life Sciences

  • Uncompromising Quality

    Quality is the cornerstone of our operations. Our stringent quality control measures ensure that each API is manufactured to the highest standards, fostering trust and confidence in our partners and end-users alike.

  • Innovation-Driven Approach

    Embracing innovation, we constantly push the boundaries of API manufacturing. Our research and development teams collaborate seamlessly to create cutting- edge solutions that address the evolving needs of the pharmaceutical industry.

  • Regulatory Excellence

    We adhere to rigorous regulatory guidelines across all phases of production. Our commitment to compliance guarantees that every API leaving our facilities is safe, reliable, and ready for integration into pharmaceutical formulations.

  • Collaborative Partnerships

    At Aurore Life Sciences, we view our clients as partners on a shared journey. Our collaborative approach ensures that we understand your unique requirements, enabling us to tailor our services to your specific needs.

  • Global Reach, Local Presence:

    With a global footprint, we are strategically positioned to serve clients worldwide while maintaining a localized and personalized touch in all interactions.

From early-stage development and process optimization to large-scale commercial manufacturing, Aurore Life Sciences offers a comprehensive suite of services. Our expertise covers a wide range of therapeutic areas, enabling us to contribute to advancements in healthcare across various domains.